GSK has published findings indicating its respiratory syncytial virus (RSV) vaccine Arexvy was associated with reduced risks of certain severe cardiopulmonary outcomes, including heart attack, stroke and exacerbations of COPD and asthma, in real-world data. 

• Observed associations: The real-world study showed lower incidences of acute cardiovascular and respiratory events following vaccination. 
• Population context: The findings reflect data from vaccine recipients in routine clinical practice, rather than controlled trial settings. 
• Implication: The results may inform understanding of Arexvy’s impact beyond RSV prevention. 

This summary is based on a press release issued by GSK.